Abstracts tagged "pediatric rheumatology and psoriatic arthritis"

Abstract Number: 2308 • 2017 ACR/ARHP Annual Meeting
The Prevalence of Comorbidities in Pediatric Psoriasis and Juvenile Psoriatic Arthritis
Cuoghi Edens¹, Angela Byun Robinson² and Maria Antonelli³, ¹Division of Pediatric Infectious Diseases and Rheumatology and Division of Rheumatology, Rainbow Babies and Children's Hospital and University Hospitals Cleveland Medical Center, Cleveland, OH, ²Division of Pediatric Infectious Diseases and Rheumatology, Case Western Reserve University School of Medicine, Rainbow Babies and Children’s Hospital, Cleveland, OH, ³Department of Medicine/Division of Rheumatology, Case Western Reserve University School of Medicine, MetroHealth Medical Center, Cleveland, OH
Background/Purpose: Adult-onset psoriasis (PsO) and psoriatic arthritis (PsA) have been associated with increased rates of diabetes, obesity, and hypertension. We sought to evaluate the prevalence…
Abstract Number: 397 • 2016 ACR/ARHP Annual Meeting
Comorbidities Associated with Pediatric Psoriatic Arthritis
Cynthia Manos¹, Rui Xiao², Alexis Ogdie³, Timothy Brandon⁴ and Pamela F. Weiss^5,6, ¹Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA, ⁴Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ⁶Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: In adults, psoriatic arthritis (PsA) is associated with an increased prevalence of obesity, hypertension, and diabetes. It is not yet known if pediatric patients…
Abstract Number: 280 • 2013 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy Of Etanercept In Paediatric Subjects With Extended Oligoarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Or Psoriatic Arthritis
Tamas Constantin¹, Ivan Foeldvari², Jelena Vojinovic³, Gerd Horneff⁴, Ruben Burgos-Vargas⁵, Irina Nikishina⁶, Jonathan Akikusa⁷, Tadej Avcin⁸, Jeffrey Chaitow⁵, Elena Koskova⁹, Bernard Lauwerys¹⁰, Jack Bukowski¹¹, Chuanbo Zang¹², Joseph Wajdula¹², Deborah Woodworth¹², Bonnie Vlahos¹³, Alberto Martini¹⁴ and Nicolino Ruperto⁵, ¹Semmelweis University, Budapest, Hungary, ²Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, ³Dept Pediatric Rheumatology, Clinical Center, School of Medicine University of Nis, Nis, Serbia, ⁴Department of Pediatrics, Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁵PRINTO, Genoa, Italy, ⁶Pediatric Department, Scientific Research Institute of Rheumatology RAMS, Moskow, Moskow, Russia, ⁷Rheumatology, Royal Childrens Hospital, Parkville, Australia, ⁸The Ljubljana University Medical Centre, Pediatric Clinic, Ljubljana, Slovenia, ⁹National Institute of Rheumatic Diseases, Piestany, Slovakia, ¹⁰Pôle de Maladies Rhumatismales, Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Brussels, Belgium, ¹¹Department of Specialty Care, Pfizer Inc, Collegeville, PA, ¹²Pfizer Inc., Collegeville, PA, ¹³Department of Specialty Care, Pfizer Inc., Collegeville, PA, ¹⁴Pediatria II, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: Etanercept (ETN) is approved for the treatment of pediatric patients with the polyarticular subtype of juvenile idiopathic arthritis (JIA). In addition, based on the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].